WallStreetZenWallStreetZen

NASDAQ: AKTX
Akari Therapeutics PLC Stock

$1.17-0.04 (-3.31%)
Updated Apr 19, 2024
AKTX Price
$1.17
Fair Value Price
$0.79
Market Cap
$18.48M
52 Week Low
$1.08
52 Week High
$5.50
P/E
N/A
P/B
-80.69x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$10.01M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-20.02
Operating Cash Flow
-$16M
Beta
0.53
Next Earnings
Apr 29, 2024
Ex-Dividend
N/A
Next Dividend
N/A

AKTX Overview

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how AKTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

AKTX ($1.17) is overvalued by 48.43% relative to our estimate of its Fair Value price of $0.79 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
AKTX ($1.17) is not significantly undervalued (48.43%) relative to our estimate of its Fair Value price of $0.79 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
AKTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more AKTX due diligence checks available for Premium users.

Be the first to know about important AKTX news, forecast changes, insider trades & much more!

AKTX News

Valuation

AKTX fair value

Fair Value of AKTX stock based on Discounted Cash Flow (DCF)
Price
$1.17
Fair Value
$0.79
Overvalued by
48.94%
AKTX ($1.17) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AKTX ($1.17) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation

AKTX price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0x
Industry
15.81x
Market
40.51x

AKTX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-80.69x
Industry
5.74x

AKTX's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
AKTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$4.4M
Liabilities
$4.6M
Debt to equity
-20.02
AKTX's short-term liabilities ($4.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AKTX's short-term assets ($4.34M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AKTX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
AKTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
AKTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

AKTX vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
AKTX$18.48M-3.64%N/A-80.69x
GLTO$18.46M-5.42%-0.47x0.57x
BIOR$18.64M+2.50%-0.08x-0.18x
VINC$18.20M-5.56%-0.45x1.62x
CDIO$18.78M-20.18%-1.32x6.35x

Akari Therapeutics Stock FAQ

What is Akari Therapeutics's quote symbol?

(NASDAQ: AKTX) Akari Therapeutics trades on the NASDAQ under the ticker symbol AKTX. Akari Therapeutics stock quotes can also be displayed as NASDAQ: AKTX.

If you're new to stock investing, here's how to buy Akari Therapeutics stock.

What is the 52 week high and low for Akari Therapeutics (NASDAQ: AKTX)?

(NASDAQ: AKTX) Akari Therapeutics's 52-week high was $5.50, and its 52-week low was $1.08. It is currently -78.8% from its 52-week high and 8.26% from its 52-week low.

How much is Akari Therapeutics stock worth today?

(NASDAQ: AKTX) Akari Therapeutics currently has 15,847,391,523 outstanding shares. With Akari Therapeutics stock trading at $1.17 per share, the total value of Akari Therapeutics stock (market capitalization) is $18.48M.

Akari Therapeutics stock was originally listed at a price of $1,600.00 in Jan 6, 2014. If you had invested in Akari Therapeutics stock at $1,600.00, your return over the last 10 years would have been -99.93%, for an annualized return of -51.44% (not including any dividends or dividend reinvestments).

How much is Akari Therapeutics's stock price per share?

(NASDAQ: AKTX) Akari Therapeutics stock price per share is $1.17 today (as of Apr 19, 2024).

What is Akari Therapeutics's Market Cap?

(NASDAQ: AKTX) Akari Therapeutics's market cap is $18.48M, as of Apr 21, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Akari Therapeutics's market cap is calculated by multiplying AKTX's current stock price of $1.17 by AKTX's total outstanding shares of 15,847,391,523.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.